Myriad Genetics Inc (NQ: MYGN )
18.21 USD -0.45 (-2.41%) Official Closing Price Updated: 4:50 PM EST, Nov 25, 2020 Add to My Watchlist
Press releases about Myriad Genetics Inc
Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.
May 28, 2020
Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
May 26, 2020
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
May 20, 2020
Thinking about buying stock in Aurora Cannabis, Cytokinetics, Quotient, Myriad Genetics, or Avaya Holdings?
May 11, 2020
From PR Newswire
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
May 11, 2020
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder
April 20, 2020
Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic
April 08, 2020
Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC
April 06, 2020
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
March 30, 2020
Myriad Announces Board of Directors Leadership Transition
March 23, 2020
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer
March 18, 2020
NASDAQ: MYGN Long-Term Investor Alert: Investigation of Potential Wrongdoing at Myriad Genetics, Inc.
February 25, 2020
San Diego, CA -- (SBWIRE) -- 02/25/2020 -- An investigation on behalf of current long term investors in Myriad Genetics, Inc. (NASDAQ: MYGN) shares over possible breaches of fiduciary duty by certain...
New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy
February 14, 2020
Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer
February 11, 2020
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Myriad Genetics, Inc., Investors (MYGN)
February 07, 2020
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Myriad Genetics, Inc., (“Myriad” or the “Company”) (NASDAQ: MYGN) concerning whether the board...
Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
February 06, 2020
Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020
January 30, 2020
Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer
January 22, 2020
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer
January 21, 2020
Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology
January 14, 2020
Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert
January 13, 2020
The Board of Directors of Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable,...
New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study
January 06, 2020
INVESTOR ALERT: Kirby McInerney LLP Launches Investigation of Myriad Genetics (MYGN) for Possible Breaches of Fiduciary Duty by Certain Officers and Directors
December 30, 2019
The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN). The investigation relates to possible breaches of...
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer
December 30, 2019